Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

MHRA accepts XOMA's proposal for phase II study of XOMA-358 in congenital hyperinsulinism

Oct. 20, 2016

Shionogi discloses ACC2 inhibitors

Oct. 20, 2016

GnHR antagonist SKI-2670 well tolerated, suppresses hormones in phase I trial

Oct. 20, 2016

Takeda Pharmaceutical patents enteropeptidase inhibitors

Oct. 19, 2016

EMA gives orphan drug designation to gene therapy program ABO-102

Oct. 19, 2016

The Medicines Company reports positive results for PCSK-9si trial

Oct. 19, 2016

EMA gives orphan drug designation to Eiger's exendin 9-39

Oct. 18, 2016

Hua reports promising phase II results of glucokinase activator HMS-5552

Oct. 17, 2016

Clementia Pharmaceuticals reports positive results from phase II study of palovarotene

Oct. 17, 2016

EMA committee recommends approval of Rekovelle

Oct. 17, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 8, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...